Over a week ago |
Hot Stocks
|
GeoVax Labs announced… GeoVax Labs announced that it will be represented during two upcoming scientific meetings, including Vaccines Summit Boston 2023 in Boston, MA, May 22-24, 2023 and CYTO 2023 in Montreal, Quebec, Canada, May 20-24, 2023. Don Diamond, Ph.D., Professor, Department of Hematology & Hematopoietic Cell Transplantation, City of Hope, will deliver a presentation titled, "Assessment of GEO-CM04S1 for Prevention of COVID-19 in Immunocompromised Cell Therapy Patients; An Open-Label Safety Study." Dr. Diamond's presentation will include a description of the development and clinical testing of GeoVax's vaccine candidate, GEO-CM04S1. CM04S1 is a next-generation COVID-19 vaccine based on the use of the MVA viral vector platform, which presents multiple antigens to the immune system to induce both antibody and T cell responses. The vaccine is designed to provide durable protection against new and continually emerging variants of COVID-19, limiting the need for frequent modification and updating. GeoVax is focusing on the clinical development of this vaccine for use in patients with impaired ability to mount adequate protective immune responses to currently available COVID-19 vaccines, to include those with certain malignancies and autoimmune disorders, cell and organ transplant patients, individuals with end-stage kidney disease receiving hemodialysis, and potentially elderly individuals who respond poorly to other vaccines. These individuals may not be able to raise or maintain protective antibody responses following receipt of first-generation mRNA vaccines, contributing to reduced vaccine efficacy. On Tuesday, May 23, Sandra Ortega-Francisco, Ph.D., Department of Hematology and Hematopoietic Cell Transplantation and Hematologic Malignancies Research Institute, City of Hope, will participate in a poster presentation titled, "Induction of multi-antigen specific T cell responses by a synthetic MVA-SARS-CoV-2 vaccine in patients with hematological malignancies." ShowHide Related Items >><< - 04/17/23
- GeoVax Labs announces expansion of next-generation vaccine rights
- 04/06/23
- GeoVax announces presentation of preliminary data of Covid vaccine candidate
- 04/05/23
- GeoVax Labs presents data from primate studies of Marburg vaccine candidate
- 02/27/23
- GeoVax announces presentation of results from clinical study of HIV therapy
- 05/08/23 Noble Capital
- GeoVax Labs initiated with an Outperform at Noble Capital
- 03/03/23 Dawson James
- GeoVax Labs initiated with a Buy at Dawson James
- 10/26/22 H.C. Wainwright
- GeoVax Labs initiated with a Buy at H.C. Wainwright
- 05/23/22 Maxim
- Maxim sees GeoVax Labs undervalued, citing its MVA vaccine in monkeypox
- 05/04/23
- GeoVax Labs reports Q1 EPS (15c), consensus (20c)
- 03/03/23
- Street Wrap: Today's Top 15 Upgrades, Downgrades, Initiations
|
Initiation
|
Noble Capital initiated… Noble Capital initiated coverage of GeoVax Labs with an Outperform rating and $6 price target. Gedeptin, its lead cancer product, is a gene-directed therapy for cancer that uses a proprietary delivery technology to deliver a gene to the cancer cells that converts an inactive prodrug into an active cytotoxic drug within the tumor cells, the analyst tells investors. The firm, which believes company fundamentals have been improving as the environment for small capitalization biotechnology company stocks has been in a long decline, expects the stock to be driven by the clinical milestones in development programs for Gedeptin and CM04S1, a next-generation COVID-19 vaccine. ShowHide Related Items >><< - 04/17/23
- GeoVax Labs announces expansion of next-generation vaccine rights
- 04/06/23
- GeoVax announces presentation of preliminary data of Covid vaccine candidate
- 04/05/23
- GeoVax Labs presents data from primate studies of Marburg vaccine candidate
- 02/27/23
- GeoVax announces presentation of results from clinical study of HIV therapy
- 03/03/23 Dawson James
- GeoVax Labs initiated with a Buy at Dawson James
- 10/26/22 H.C. Wainwright
- GeoVax Labs initiated with a Buy at H.C. Wainwright
- 05/23/22 Maxim
- Maxim sees GeoVax Labs undervalued, citing its MVA vaccine in monkeypox
- 05/04/23
- GeoVax Labs reports Q1 EPS (15c), consensus (20c)
- 03/03/23
- Street Wrap: Today's Top 15 Upgrades, Downgrades, Initiations
|
Earnings
|
GeoVax reported cash… GeoVax reported cash balances of $23,849,860 at March 31 as compared to $27,612,732 at December 31, last year a decrease of $3,762,872. David Dodd, GeoVax's Chairman and CEO, commented, "During the first quarter of 2023, our corporate focus continued to be on the advancement of our ongoing clinical trials for our Gedeptin cancer therapy targeting advanced head and neck cancers and CM04S1, our next-generation SARS-CoV-2 vaccine. Positive initial data was recently presented for CM04S1 during the World Vaccine Congress, and our Gedeptin trial has expanded to additional NCI-designated Cancer Centers, allowing us to accelerate our patient enrollment efforts; we look forward to completing enrollment for this trial in the very near future. I look forward to reporting further progress on each of our ongoing clinical trials during the remainder of the year." Dodd further commented, "In addition to clinical progress, the first quarter was filled with many notable achievements for GeoVax. Significant progress has been made in developing a high-yield, high-capacity, continuous avian cell line system for manufacturing our MVA-based vaccines and immunotherapies, such as CM04S1. We believe this will provide GeoVax the ability to respond to large-scale world needs in a timely manner. Additionally, the recent expansion of our CM04S1 rights to include development for Mpox and smallpox adds to other rights we previously secured from the NIH covering preclinical, clinical and commercial uses of the NIH-MVA, potentially adding significant value to our MVA-based vaccines under development." ShowHide Related Items >><< - 04/17/23
- GeoVax Labs announces expansion of next-generation vaccine rights
- 04/06/23
- GeoVax announces presentation of preliminary data of Covid vaccine candidate
- 04/05/23
- GeoVax Labs presents data from primate studies of Marburg vaccine candidate
- 02/27/23
- GeoVax announces presentation of results from clinical study of HIV therapy
- 03/03/23 Dawson James
- GeoVax Labs initiated with a Buy at Dawson James
- 10/26/22 H.C. Wainwright
- GeoVax Labs initiated with a Buy at H.C. Wainwright
- 05/23/22 Maxim
- Maxim sees GeoVax Labs undervalued, citing its MVA vaccine in monkeypox
- 03/03/23
- Street Wrap: Today's Top 15 Upgrades, Downgrades, Initiations
|
Over a month ago |
Hot Stocks
|
GeoVax Labs announced the… GeoVax Labs announced the expansion of its rights under its exclusive license agreement with City of Hope, COH, a world-renowned cancer research and treatment organization, to include development and commercialization rights against orthopoxviruses in addition to SARS-CoV-2. The original license agreement with COH provides GeoVax exclusive worldwide rights to key patents, including the use of COH's proprietary synthetic MVA process, for developing COVID-19 vaccines, including GEO-CM04S1, a multi-antigenic SARS-CoV-2 investigational vaccine expressing the spike and nucleocapsid antigens of the SARS-CoV-2 virus. CM04S1 is currently being studied in two ongoing Phase 2 clinical trials. The amendment to the license announced today grants GeoVax an expanded field of use to develop vaccine products, such as CM04S1, which target the prevention, reduction, amelioration or treatment of COVID-19 to also include targeting the prevention, reduction, amelioration or treatment of diseases caused by a virus within the orthopoxvirus genus. Orthopoxviruses include Mpox, smallpox, and other viruses that cause disease in humans. ShowHide Related Items >><< - 04/06/23
- GeoVax announces presentation of preliminary data of Covid vaccine candidate
- 04/05/23
- GeoVax Labs presents data from primate studies of Marburg vaccine candidate
- 02/27/23
- GeoVax announces presentation of results from clinical study of HIV therapy
- 02/15/23
- GeoVax, EmVenio enters collaboration to expand Phase 2 COVID-19 booster trial
- 03/03/23 Dawson James
- GeoVax Labs initiated with a Buy at Dawson James
- 10/26/22 H.C. Wainwright
- GeoVax Labs initiated with a Buy at H.C. Wainwright
- 05/23/22 Maxim
- Maxim sees GeoVax Labs undervalued, citing its MVA vaccine in monkeypox
- 03/03/23
- Street Wrap: Today's Top 15 Upgrades, Downgrades, Initiations
|
Hot Stocks
|
GeoVax Labs presented an… GeoVax Labs presented an update on the development of its SARS-CoV-2 vaccine, GEO-CM04S1, including preliminary data from an ongoing Phase 2 clinical trial, during the 23rd Annual World Vaccine Congress taking place in Washington, DC. The presentation, titled "COVID-19 Vaccine CM04S1; A Superior Viral Platform Alternative for Eliciting Durable T Cell Responses in Immunocompromised Hematologic Malignancy Patients," was delivered by Dr. Don Diamond, Department of Hematology & Hematopoietic Cell Transplantation, City of Hope. Based on data from animal models and a completed Phase 1 clinical study, vaccine-induced immune responses were shown to recognize both early and later variants of SARS-CoV-2, including the Omicron variant. Vaccines of this format should not require repeated modification and updating. Diamond's presentation included unpublished data from the open-label portion of the Phase 2 trial of CM04S1 in patients undergoing hematological cancer treatment. The preliminary analysis indicates CM04S1 is highly immunogenic in these patients, inducing both antibody responses, including neutralizing antibodies, and T cell responses. These data support the planned progression of the Phase 2 clinical study, which will include a direct comparison to currently approved mRNA vaccines. CM04S1 continues to advance in a second Phase 2 clinical trial as a booster for healthy patients who have previously received the Pfizer or Moderna mRNA vaccine. Data from these studies will form the basis for comparing vaccine potential in unique patient groups as well as the general population, the company said. ShowHide Related Items >><< - 04/05/23
- GeoVax Labs presents data from primate studies of Marburg vaccine candidate
- 02/27/23
- GeoVax announces presentation of results from clinical study of HIV therapy
- 02/15/23
- GeoVax, EmVenio enters collaboration to expand Phase 2 COVID-19 booster trial
- 02/08/23
- GeoVax announces progress in establishing continuous cell line system
- 03/03/23 Dawson James
- GeoVax Labs initiated with a Buy at Dawson James
- 10/26/22 H.C. Wainwright
- GeoVax Labs initiated with a Buy at H.C. Wainwright
- 05/23/22 Maxim
- Maxim sees GeoVax Labs undervalued, citing its MVA vaccine in monkeypox
- 03/03/23
- Street Wrap: Today's Top 15 Upgrades, Downgrades, Initiations
|
Hot Stocks
|
GeoVax Labs announced the… GeoVax Labs announced the presentation of data from recent nonhuman primate studies of GeoVax's vaccine candidate against Marburg virus, during the 23rd Annual World Vaccine Congress taking place in Washington, DC. The data were presented by Dr. Jason Comer, Associate Professor, Sealy Institute for Vaccine Sciences, University of Texas Medical Branch, in a presentation titled "Preclinical Capabilities at the University of Texas Medical Branch: Evaluating Candidate Vaccines and Immunotherapeutics against Sudan Ebola Virus," during the session on Emerging and Re-Emerging Diseases. Dr. Comer's presentation focused on UTMB's services for regulated, nonclinical studies, and included data from recent studies conducted on behalf of GeoVax. Following encouraging results showing complete protection from Marburg virus challenge in guinea pigs, GeoVax's vaccine efficacy studies targeting Marburg virus and Sudan Ebola virus disease were contracted to UTMB through the National Institute of Allergy and Infectious Disease Preclinical Services. Of particular interest, immunization with GeoVax's vaccine candidate conferred 80% survival in cynomolgus macaques following a lethal dose of Marburg virus. Vaccination protected nonhuman primates from viremia, weight loss and death following challenge with a lethal Marburg virus dose. Evaluation of immune responses following vaccination demonstrated the presence of both neutralizing antibodies and functional T cells, indicating a breadth of responses that combine for optimal protection. The work conducted by UTMB built upon earlier studies demonstrating that guinea pigs vaccinated with GEO-MM01 were 100% protected against death and disease caused by the Angola strain of Marburg virus. The vaccine induced immune responses were characterized by Marburg virus-specific binding and neutralizing antibodies as well as other effector functions like antibody-dependent phagocytosis. The Angola strain is the most virulent strain of Marburg Virus characterized by up to a 90% fatality rate in humans and a successful vaccination approach is of paramount public health importance. ShowHide Related Items >><< - 02/27/23
- GeoVax announces presentation of results from clinical study of HIV therapy
- 02/15/23
- GeoVax, EmVenio enters collaboration to expand Phase 2 COVID-19 booster trial
- 02/08/23
- GeoVax announces progress in establishing continuous cell line system
- 02/07/23
- GeoVax Labs expands Gedeptin clinical research
- 03/03/23 Dawson James
- GeoVax Labs initiated with a Buy at Dawson James
- 10/26/22 H.C. Wainwright
- GeoVax Labs initiated with a Buy at H.C. Wainwright
- 05/23/22 Maxim
- Maxim sees GeoVax Labs undervalued, citing its MVA vaccine in monkeypox
- 03/03/23
- Street Wrap: Today's Top 15 Upgrades, Downgrades, Initiations
|
On The Fly
|
Want to get stock-moving… ShowHide Related Items >><< - 01/25/23
- Vornado, Rudin complete 350 Park Avenue, 40 East 52nd Street transactions
- 01/18/23
- Vornado cuts quarterly dividend to 37.5c per share
- 12/28/22
- Vornado falls 2% after exiting S&P500 index
- 12/28/22
- Vornado Realty Trust to replace RXO in the S&P MidCap 400 at open on January 5
- 11/09/22
- Trade Desk jumps 8% to $47.01 after Q3 results beat estimates
- 10/04/22
- Trade Desk sees long-term adjusted EBITDA at 40%
- 01/17/23
- TowneBank completes Farmers Bank merger
- 01/05/23
- TowneBank names Clark COO
- 12/16/22
- TowneBank expects to complete Farmers Bank merger in early January
- 11/23/22
- TowneBank announces retirement of president and COO Brad Schwartz
- 03/01/23
- Stellantis, Koc Holding strengthens Tofas JV, enhances partnership in Turkiye
- 02/28/23
- Stellantis announces $155M investment in three Indiana plants
- 02/28/23
- Stellantis announces $155M investment in three Indiana plants
- 02/27/23
- Stellantis taking 14.2% equity stake in McEwen Copper
- 02/08/23
- RadNet launches Enhanced Breast Cancer Detection service
- 12/19/22
- RadNet: DeepHealth receives FDA clearance for Saige-Density software
- 11/28/22
- RadNet's Aidence, Google Health enter collaboration for lung cancer screening
- 11/28/22
- RadNet subsidiary, Google Health announce agreement to license AI research model
- 01/12/23
- Porsche Cars North America reports 2022 U.S. retail deliveries of 70,065
- 12/16/22
- Volkswagen shareholders approve special dividend from Porsche IPO
- 11/28/22
- Hagerty opens Garage + Social Van Nuys, partners with Long , Emory
- 09/18/22
- Fly Intel: Top five weekend stock stories
- 02/14/23
- Nelson Peltz's Trian buys Disney, cuts Sysco in Q4
- 01/19/23
- Procter & Gamble says 'on track' to deliver FY23 guidance
- 01/19/23
- Procter & Gamble says Q2 growth broad based across business units
- 01/19/23
- Procter & Gamble reports Q2 gross margin down 160 bps vs. a year ago
- 02/01/23
- Itron expands collaboration with Smart Energy Water
- 01/10/23
- Itron to partner with Qatar District Cooling Company on energy operations
- 01/10/23
- Quantum names Kenneth Gianella as CFO, succeeding Mike Dodson
- 12/13/22
- Itron signs contract with GRU to modernize infrastructure
- 02/27/23
- GeoVax announces presentation of results from clinical study of HIV therapy
- 02/15/23
- GeoVax, EmVenio enters collaboration to expand Phase 2 COVID-19 booster trial
- 02/08/23
- GeoVax announces progress in establishing continuous cell line system
- 02/07/23
- GeoVax Labs expands Gedeptin clinical research
- 10/13/22
- Imara to combine with Enliven Therapeutics in all-stock transaction
- $305.27 /
+3.755 (+1.25%) - 02/23/23
- Domino's Pizza falls -10.2%
- 02/23/23
- Domino's Pizza sees FY23 CapEx $90M-$100M
- 02/23/23
- Domino's Pizza cuts two-to three-year outlook for global retail sales growth
- 12/15/22
- Domino's Pizza to enter Uruguay and Latvia
- 12/08/22
- Douglas Emmett cuts quarterly cash dividend to 19c per share from 28c
- 12/08/22
- Douglas Emmett announces $300M share repurchase authorization
- $10.77 /
-5.235 (-32.72%) - 03/03/23
- CareDx comments on MolDX publication of new billing, coding article
- 03/02/23
- CareDx trading resumes
- 03/02/23
- CareDx trading halted, volatility trading pause
- 02/16/23
- CareDx to present cellular transplant progress at Tandem Meetings
- 01/09/23
- Bilibili prices note repurchases, equity offering
- 12/27/22
- China stocks rising with borders set to reopen on January 8
- 12/23/22
- PCAOB chair 'applauds' Congressional action to shorten HFCAA timeline
- 11/29/22
- Bilibili jumps 11% to $13.95 after Q3 earnings beat and guidance
- $10.77 /
-5.235 (-32.72%) - 03/03/23 Craig-Hallum
- CareDx downgraded to Hold at Craig-Hallum after Medicare 'worst case scenario'
- 03/03/23 Craig-Hallum
- CareDx downgraded to Hold from Buy at Craig-Hallum
- 03/03/23 Raymond James
- CareDx double downgraded to Market Perform at Raymond James
- 03/03/23 Raymond James
- CareDx downgraded to Market Perform from Strong Buy at Raymond James
- 03/03/23 RBC Capital
- Stellantis upgraded to Outperform from Sector Perform at RBC Capital
- 02/24/23 RBC Capital
- Stellantis price target raised to EUR 19 from EUR 18 at RBC Capital
- 01/30/23 Berenberg
- Stellantis price target lowered to EUR 18 from EUR 19 at Berenberg
- 01/25/23 Morgan Stanley
- Stellantis price target lowered to EUR 18 from EUR 18.50 at Morgan Stanley
- 03/03/23 JPMorgan
- Procter & Gamble upgraded to Overweight from Neutral at JPMorgan
- 03/01/23 UBS
- Procter & Gamble upgraded to Buy from Neutral at UBS
- 02/16/23 Citi
- Citi launches beverage, personal space with six buys, two sells
- 02/16/23 Citi
- Procter & Gamble initiated with a Buy at Citi
- 03/03/23 Raymond James
- RadNet upgraded to Outperform on AI visibility at Raymond James
- 03/03/23 Raymond James
- RadNet upgraded to Outperform from Market Perform at Raymond James
- 09/29/22 Clarus
- Biogen's lecanemab could be positive revenue driver for Akumin, says Clarus
- 03/03/23 Citi
- Bilibili upgraded to Buy at Citi with growth seen picking up
- 03/03/23 Citi
- Bilibili upgraded to Buy from Neutral at Citi
- 12/13/22 Bernstein
- Bilibili raised to Market Perform at Bernstein with short case 'less compelling'
- 12/13/22 Bernstein
- Bilibili upgraded to Market Perform from Underperform at Bernstein
- 03/03/23 JPMorgan
- Itron downgraded to Underweight from Neutral at JPMorgan
- 02/28/23 Piper Sandler
- Itron price target raised to $58 from $48 at Piper Sandler
- 02/28/23 Baird
- Itron price target raised to $52 from $40 at Baird
- 02/02/23 TD Cowen
- Itron price target raised to $72 from $55 at Cowen
- $305.27 /
+3.755 (+1.25%) - 03/03/23
- Domino's Pizza downgraded at Gordon Haskett on lower long-term growth algorithm
- 03/03/23
- Domino's Pizza downgraded to Hold from Buy at Gordon Haskett
- 02/28/23 Stifel
- Domino's Pizza price target lowered to $300 from $320 at Stifel
- 02/28/23 Northcoast
- Domino's Pizza downgraded to Neutral from Buy at Northcoast
- 03/03/23 BMO Capital
- Vornado downgraded to Underperform from Market Perform at BMO Capital
- 01/04/23 Deutsche Bank
- Vornado price target lowered to $22 from $25 at Deutsche Bank
- 01/04/23 Mizuho
- Vornado upgraded to Neutral from Underperform at Mizuho
- 12/14/22 Citi
- Vornado downgraded to Sell from Neutral at Citi
- 03/03/23 BMO Capital
- Douglas Emmett downgraded to Underperform from Market Perform at BMO Capital
- 01/09/23 Credit Suisse
- Douglas Emmett downgraded to Neutral from Outperform at Credit Suisse
- 01/03/23 Jefferies
- Douglas Emmett downgraded at Jefferies on potential for worst case for offices
- 01/02/23 Jefferies
- Douglas Emmett downgraded to Underperform from Hold at Jefferies
- 03/03/23 HSBC
- Porsche downgraded to Hold from Buy at HSBC
- 01/30/23 Berenberg
- Porsche price target raised to EUR 120 from EUR 96.80 at Berenberg
- 01/25/23 Morgan Stanley
- Porsche price target raised to EUR 90 from EUR 82.50 at Morgan Stanley
- 01/11/23 Exane BNP Paribas
- Porsche downgraded to Neutral from Outperform at Exane BNP Paribas
- 03/03/23 BTIG
- Trade Desk initiated with a Neutral at BTIG
- 02/17/23 Citi
- Trade Desk price target raised to $76 from $60 at Citi
- 02/16/23 Morgan Stanley
- Trade Desk price target raised to $58 from $50 at Morgan Stanley
- 02/16/23 DA Davidson
- Trade Desk price target raised to $76 from $56 at DA Davidson
- 03/03/23 TD Cowen
- Enliven initiated with an Outperform at TD Cowen
- 03/03/23 Dawson James
- GeoVax Labs initiated with a Buy at Dawson James
- 10/26/22 H.C. Wainwright
- GeoVax Labs initiated with a Buy at H.C. Wainwright
- 05/23/22 Maxim
- Maxim sees GeoVax Labs undervalued, citing its MVA vaccine in monkeypox
- 03/03/23 Cantor Fitzgerald
- Nextracker initiated with an Overweight at Cantor Fitzgerald
- 03/03/23 Cantor Fitzgerald
- Nextracker initiated with an Overweight at Cantor Fitzgerald
- 03/03/23 Raymond James
- TowneBank resumed with an Outperform at Raymond James
- 03/03/23 Raymond James
- TowneBank initiated with an Outperform at Raymond James
- 02/17/23 Piper Sandler
- TowneBank resumed with an Overweight at Piper Sandler
- 02/13/23
- Vornado reports Q4 adjusted FFO 72c, consensus 67c
- 02/15/23
- Trade Desk sees Q1 revenue at least $363M, consensus $360.94M
- 02/15/23
- Trade Desk reports Q4 non-GAAP EPS 38c, consensus 36c
- 02/14/23
- Notable companies reporting before tomorrow's open
- 01/26/23
- TowneBank reports Q4 adjusted EPS 65c vs 55c last year
- 10/27/22
- TowneBank reports Q3 EPS 69c vs 69c last year
- 11/03/22
- Stellantis reports Q3 revenue EUR 42.1B vs. EUR 32.6B last year
- 02/28/23
- RadNet sees 2023 revenue $1.53B-$1.58B, consensus $1.46B
- 02/28/23
- RadNet reports Q4 adjusted EPS 11c, consensus 15c
- 11/09/22
- RadNet still sees 2022 revenue $1.36B-$1.41B, consensus $1.4B
- 11/09/22
- RadNet reports Q3 adjusted EPS 9c, consensus 16c
- 01/19/23
- Procter & Gamble raises FY23 sales growth outlook
- 01/19/23
- Procter & Gamble reports Q2 core EPS $1.59, consensus $1.59
- 01/18/23
- Notable companies reporting before tomorrow's open
- 02/27/23
- Itron sees FY23 EPS 70c-$1.10, consensus $1.53
- 02/27/23
- Itron sees Q1 EPS 5c-15c, consensus 21c
- 02/27/23
- Itron reports Q4 EPS 71c, vs 75c last year
- 11/03/22
- Itron sees Q4 EPS 0c- 15c, consensus 34c
- $305.27 /
+3.755 (+1.25%) - 02/23/23
- Domino's Pizza reports Q4 EPS $4.43, consensus $3.95
- 02/22/23
- Notable companies reporting before tomorrow's open
- 10/13/22
- Domino's Pizza reports Q3 EPS $2.79, consensus $2.97
- 02/07/23
- Douglas Emmett sees FY23 FFO $1.87-$1.93, consensus $1.97
- 02/07/23
- Douglas Emmett reports Q4 FFO 51c, consensus 52c
- 11/03/22
- Douglas Emmett narrows FY22 FFO view to $2.03-$2.05 from $2.03-$2.07
- 11/03/22
- Douglas Emmett reports Q3 FFO 51c, consensus 51c
- $10.77 /
-5.235 (-32.72%) - 02/27/23
- CareDx sees FY23 revenue $328M-$338M, consensus $338.42M
- 02/27/23
- CareDx reports Q4 adjusted EPS (7c), consensus (9c)
- 01/09/23
- CareDx sees FY23 revenue $321.3M-$321.6M, consensus $347.69M
- 01/09/23
- CareDx reports preliminary Q4 revenue $81.9M-$82.2M, consensus $81.54M
- 03/02/23
- Bilibili reports Q4 EPS (48c), consensus (51c)
- 11/29/22
- Bilibili sees Q4 revenue RMB 6B-RMB 6.2B
- 11/29/22
- Bilibili reports Q3 adjusted EPS (63c), consensus (65c)
- 09/08/22
- Bilibili sees Q3 revenue RMB 5.6B - RMB 5.8B
|
Initiation
|
Dawson James analyst… Dawson James analyst Jason Kolbert initiated coverage of GeoVax Labs with a Buy rating and $4 price target. Under the leadership of David Dodd, GeoVax has "transformed itself" and now has "two assets that are worthy of attention," the analyst tells investors. Gedeptin, a gene therapy for solid tumors, is now in Phase 1/2 trials in advanced head and neck squamous cell carcinoma, or HNSCC, and GEO-CM02, a COVID-19 vaccine for immunocompromised patients, the firm said. ShowHide Related Items >><< - 02/27/23
- GeoVax announces presentation of results from clinical study of HIV therapy
- 02/15/23
- GeoVax, EmVenio enters collaboration to expand Phase 2 COVID-19 booster trial
- 02/08/23
- GeoVax announces progress in establishing continuous cell line system
- 02/07/23
- GeoVax Labs expands Gedeptin clinical research
- 10/26/22 H.C. Wainwright
- GeoVax Labs initiated with a Buy at H.C. Wainwright
- 05/23/22 Maxim
- Maxim sees GeoVax Labs undervalued, citing its MVA vaccine in monkeypox
|
Hot Stocks
|
GeoVax Labs announced the… GeoVax Labs announced the presentation of results from a clinical study of a combinational HIV therapy that included GeoVax's HIV vaccine candidate, MVA62B. The data were presented at the Conference on Retroviruses and Opportunistic Infections held February 19-22, 2023, in Seattle, Washington. The data were generated, in a clinical trial led by researchers at the University of California, San Francisco, to develop a combinational therapy aimed at reducing or eliminating viral replication in the absence of antiviral medications in HIV-positive individuals. The primary objectives of the proof-of-concept trial were to assess the safety and tolerability of the combinational therapy and to determine the viral load "set-point" during antiviral treatment interruption. Secondary objectives were to assess immune responses and changes in viral reservoir status. The clinical trial was led by Steven Deeks, M.D. of UCSF, a world leader in therapeutic approaches to HIV infections, and was one of the most comprehensive tests to date for the ability of synergistic approaches to control HIV infection. The studies were conducted with funding from amfAR, The Foundation for AIDS Research. ShowHide Related Items >><< - 02/15/23
- GeoVax, EmVenio enters collaboration to expand Phase 2 COVID-19 booster trial
- 02/08/23
- GeoVax announces progress in establishing continuous cell line system
- 02/07/23
- GeoVax Labs expands Gedeptin clinical research
- 01/25/23
- GeoVax Labs receives notice of allowance for Zika vaccine patent
- 10/26/22 H.C. Wainwright
- GeoVax Labs initiated with a Buy at H.C. Wainwright
- 05/23/22 Maxim
- Maxim sees GeoVax Labs undervalued, citing its MVA vaccine in monkeypox
|